Physician profile
Timothy Eric Halterman
NPI 1992921316
$2,503.19
in general payments reported to CMS, 2019-2025
19 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2021: $33.93 · 2022: $378 · 2023: $451 · 2024: $345 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,798 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,797.50 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,179.10 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $153.28 | 2024-2025 | Vowst |
| Genzyme Corporation | $152.45 | 2022-2025 | |
| Boston Scientific Corporation | $144.93 | 2023-2024 | Resolution 360 Ultra Clip, Watchman Flx |
| Ipsen Biopharmaceuticals, INC | $141.21 | 2025 | Iqirvo, Bylvay |
| Covidien LP | $119.97 | 2019 | |
| Gilead Sciences, INC. | $105.38 | 2019 | |
| Janssen Biotech, INC. | $84.78 | 2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Madrigal Pharmaceuticals | $65.97 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $58.76 | 2022-2025 | Entyvio |
| Intercept Pharmaceuticals, INC. | $39.19 | 2022-2023 | Ocaliva |
| Apollo Endosurgery US INC | $37.98 | 2023 | Overstitch Endoscopic Suturing System |
| Pfizer INC. | $36.58 | 2025 | |
| Qol Medical, LLC | $31.96 | 2025 | Sucraid |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.81 | 2022-2023 | Xifaxan |
| Biocon Biologics INC | $27.23 | 2025 | Yesintek |
| Regeneron Healthcare Solutions, INC. | $14.33 | 2025 | Dupixent |
| Lilly USA, LLC | $13.79 | 2025 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Halterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.